|
|
|
|
| LEADER |
05154nam a2200349 u 4500 |
| 001 |
EB001839583 |
| 003 |
EBX01000000000000001003572 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Coeytaux, Remy R.
|
| 245 |
0 |
0 |
|a Systematic review of ECG-based signal analysis technologies for evaluating patients with acute coronary syndrome
|h Elektronische Ressource
|c prepared for Agency for Healthcare Research and Quality ; [prepared by] Duke Evidence-based Practice Center ; Remy R. Coeytaux, Philip J. Leisy, Galen S. Wagner, Amanda J. McBroom, Cynthia L. Green, Liz Wing, R. Julian Irvine, Gillian D. Sanders
|
| 260 |
|
|
|a Rockville, Maryland
|b Agency for Healthcare Research and Quality
|c June 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (viii, 10, 73 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Acute Coronary Syndrome / diagnosis
|
| 653 |
|
|
|a Signal Processing, Computer-Assisted
|
| 653 |
|
|
|a Electrocardiography / methods
|
| 653 |
|
|
|a Diagnosis, Computer-Assisted / methods
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Duke University Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Technology assessment
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK280225
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a CONCLUSIONS: Existing research is largely insufficient to confidently inform the appropriate use of ECG-based signal analysis technologies in diagnosing CAD and/or ACS. Further research is needed to better describe the performance characteristics of these devices to determine in what circumstances, if any, these devices might precede, replace, or add to the standard ECG in test strategies to identify clinically significant CAD in the patient population of interest. To fully assess the impact of these devices on diagnostic strategies for patients with chest pain, test performance needs to be linked to clinically important outcomes through modeling or longitudinal studies
|
| 520 |
|
|
|a Meta-analysis of eight of these studies determined a 68.4 percent sensitivity (95% CI, 35.1 to 89.7) and 91.4 percent specificity (CI, 83.6 to 95.7) for the PRIME ECG in detecting MI (with all but one study using elevated cardiac biomarkers as the reference standard) compared with 40.5 percent sensitivity (CI, 19.6 to 65.5) and 95.0 percent specificity (CI, 87.9 to 98.0) for the standard 12-lead ECG. Differences in test performance between the PRIME ECG and 12-lead ECG are not statistically significant as judged by the overlapping confidence intervals. A single study of LP 3000 demonstrated that QRS prolongation on the signal-averaging ECG was associated with a sensitivity and specificity of 70 percent and 89 percent, respectively, compared with 56 percent and 89 percent for ST changes detected by 12-lead ECG. The improved sensitivity of the signal-averaging ECG versus the 12-lead ECG in that study was statistically significant (p<0.01).
|
| 520 |
|
|
|a OBJECTIVES: To summarize the clinical and scientific evidence for commercially available ECG-based signal analysis technologies used or proposed to be used to evaluate patients at low to intermediate risk for coronary artery disease (CAD) who have chest pain or other symptoms suggestive of acute coronary syndrome (ACS). DATA SOURCES: Searches of gray literature sources, MEDLINE(r), EMBASE(r), and the Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects. REVIEW METHODS: We conducted a systematic search of English-language literature to identify published evidence for ECG-based technologies that may improve the diagnosis of CAD and/or ACS through signal analysis or other forms of advanced data transformation. For inclusion, a technology had to be (1) a physical device that obtains and interprets information about the electrical activity of the heart in ways that are different from the standard 12-lead ECG, (2) cleared for marketing by the U.S.
|
| 520 |
|
|
|a Food and Drug Administration (FDA) and commercially available in the United States with feasible implementation, (3) tested in patients at low to intermediate risk for CAD who have a clinical presentation consistent with ACS, and (4) reported in a peer-reviewed, published study that reports performance characteristics, effects on diagnostic or treatment decisions, or effects on patient outcomes. Reviewers worked in pairs to extract data, assess applicability, and evaluate the quality of each study. We used a bivariate random-effects generalized linear regression model to compute summary estimates of sensitivity and specificity. RESULTS: We identified eight commercially available, FDA-cleared ECG-based devices proposed for use to diagnose CAD or detect ACS. Of these, published evidence meeting inclusion criteria was available for only two devices: PRIME ECG and LP 3000. PRIME ECG test performance was reported in 10 studies.
|